Trial Profile

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KAN 101 (Primary)
Indications Coeliac disease
Focus Adverse reactions; First in man
Acronyms ACeD
Sponsors Anokion; Kanyos Bio

Most Recent Events

17 Oct 2023 Results of pharmacodynamic demonstration of immunological tolerance induced by Kan-101, presented at the 31st United European Gastroenterology Week
12 Oct 2023 According to an Anokion Media Release, the company will look forward to discussing the data from this study with the scientific and medical community.
12 Oct 2023 According to an Anokion Media Release, data from this study will be presented at the United European Gastroenterology (UEG) Week 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com